Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer

Pier Paolo Maria Berton Giachetti(University of Milan), Carmen Criscitiello(University of Milan), Paola Zagami(University of Milan), Claudio Vernieri(IFOM), Sara Gandini(European Institute of Oncology), Eleonora Nicolò(Cornell University), Emma Zattarin(University of Modena and Reggio Emilia), Fabiola Giudici(University of Padua), Chiara Corti(University of Milan), Beatrice Taurelli Salimbeni(European Institute of Oncology), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Botticelli(Policlinico Umberto I), Carmine De Angelis(Baylor College of Medicine), Dario Trapani(Harvard University), Simone Scagnoli(Sapienza University of Rome), Elisabetta Munzone(Istituti di Ricovero e Cura a Carattere Scientifico), Ambra Carnevale Schianca(University of Milan), Giampaolo Bianchini(Vita-Salute San Raffaele University), Annarita Verrazzo(Scuola Superiore Meridionale), Stefania Morganti(Broad Institute), Caterina Sposetti(Harvard University), Mario Giuliano(Regione Campania), Giulia Viale(Istituti di Ricovero e Cura a Carattere Scientifico), Roberta Scafetta(Università Campus Bio-Medico), Matteo Lambertini(Ospedale Policlinico San Martino), Maria Grazia Razeti(Ospedale Policlinico San Martino), Antonio Marra(Memorial Sloan Kettering Cancer Center), Laura Boldrini(University of Milan), Angela Espósito(European Institute of Oncology), Bianca Malagutti(University of Milan), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Curigliano(University of Milan)
JAMA Network Open
February 21, 2025
Cited by 11


Related Papers